FDA APPROVES SEVEN PMAs IN SEPTEMBER, BRINGING FISCAL 1994 TOTAL TO 26
This article was originally published in The Gray Sheet
Executive Summary
FDA pushed through seven premarket approval applications during the month of September, enough to edge the total number of approvals in fiscal 1994 past its FY 1993 total of 24. The 26 approvals are the most for the agency since 1991 when 27 PMAs were approved.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.